Archive | February, 2010

Microfluidics (MFLU.OB) Update-Turnaround intact

Microfluidics announced Year-End 2009 and Q4 results yesterday and delivered numbers pretty much according to plan. Q4 Income was $80k; Gross margin at 60% Achieved $525k EBITA for Full Year; R&D was cut to $449k for Q4 but management says no impact on new products Generated $15.7M Revenue for 2009 a 6% increase for 2008; […]

Continue Reading 0

Clinical Diagnostics Part 2: market sector poised for growth

The drive to reduce healthcare costs and perform Comparative Effectiveness Research can get support from next generation diagnostic tests. A recent article by Bill Malone in Clinical Laboratory News, February 2010 Vol.36 No.2, presents an optimistic scenario for the In Vitro Diagnostics (IVD) Market. Referencing a report from the Embargo Group of Austin,Tx, a recent […]

Continue Reading 0

Clinical Diagnostics Part 1: a sector poised for growth

Many of the issues coming out of the  healthcare reform discussion:  rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have  caused concern among investors and limited returns in the healthcare sector. Although M&A activity has picked up, funding for venture start-ups. equity for public companies and IPOs’ is down to […]

Continue Reading 0

Complete Genomics

Complete Genomics 2/18/10                       Molecular Diagnostics and Genomics “Powering large-scale human genome studies”. Private Company Summary Complete Genomics(CGI) provides high quality, affordable DNA sequencing for commercial- scale research of the genetic mechanisms underlying drug responses and complex diseases. Customers receive assembled sequences and variant reports […]

Continue Reading 0

ISIS and GENZ meet trial goal; ISIS stock sells off

Clinical Profile concerns spur a big sell-off : ISIS shares down 14.6% to $9.40 on volume of 10.6M shares The Mipomersen Phase 3 study in patients with Heterozygous Familial Hypochesterolemia, a genetic disorder, met its primary endpoint but investors were worried about potential side effects such as liver enzyme elevations. The trial goal was met […]

Continue Reading 0

New Coverage: genomics and diagnostics-Genomic Health(GHDX)

Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions (Personalized Medicine, Pharmacogenomics). In 2004 Genomic Health launched […]

Continue Reading 0

Microfluidics (MFLU.OB-$0.90) -a leader in advanced nano-material processing for a variety of industries

Microfluidics (MFLU.OB-$0.90) -a leader in advanced, nano-material, processing for a variety of industries A turn-around play with value characteristics This is a “heads-up” on a special report that we will issue post-earnings within two weeks on the nanotechnology small cap Microfluidics International Corp.. The Company sells high pressure microfluidic processors that are used to create […]

Continue Reading 0